Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431543 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
A Phase 2 study, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT05431543: Completed Phase 2 study, sponsored by LENZ Therapeutics.
NCT05431543 is a Phase 2 study that has completed, run by LENZ Therapeutics. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05431543, a Phase 2 study, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Primary Outcome
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision
Interventions
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine ophthalmic solution
- DRUG Vehicle proprietary ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-08-06 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
What the finished NCT05431543 record still lists
NCT05431543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 3 interventions - of which Aceclidine+Brimonidine combination ophthalmic solution is the first listed.
NCT05431543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05431543 about?
NCT05431543 is a clinical study titled "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia". To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
What is the current status of trial NCT05431543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2022-08-06. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT05431543?
The interventions under investigation include: Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine ophthalmic solution (DRUG), Vehicle proprietary ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05431543?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05431543's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI